New artificial intelligence software that can evaluate coronary CT scans to automatically assess soft plaques were by far the biggest technology advance discussed at the Society of Cardiovascular Computed Tomography (SCCT) 2022 meeting. 

A Canadian manufacturer of positron emission tomography equipment has received FDA’s OK to market a small-footprint scanner that images targeted organs bearing radiotracers at close range.

Eric Williamson, MD, MSCCT, the 2021-2022 president of the Society of Cardiovascular Computed Tomography (SCCT) and professor of radiology at Mayo Clinic, shared his key takeaways from the SCCT 2022 conference. 

The document includes updated classification to established a framework for stenosis, plaque burden and plaque modifiers, including assessment of CT-FFR or myocardial CT perfusion.

One of the largest private health insurers in the U.S. has gone from considering hybrid PET/CT for cardiac indications “experimental/investigational” to displaying willingness to pay for the modality. 

According to a new SCAI statement, the FDA's recommendation would result in "far-reaching consequences" across multiple specialties. 

This week in AJR, experts shared how they were able to reduce FDG PET scan acquisition times by 33%, thus reducing the amount of total radiation exposure to more vulnerable pediatric patients. 

The American Medical Association Board of Delegates approved a policy calling on payers to reimburse for the drug regadenoson and not to employ payment policies that push for cardiologists to change the drug they use for pharmacologic stress for one that is considered less safe.